Wall Street analysts expect Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report sales of $610,000.00 for the current quarter, Zacks reports. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $700,000.00. Arrowhead Pharmaceuticals reported sales of $9.34 million in the same quarter last year, which indicates a negative year over year growth rate of 93.5%. The company is expected to report its next quarterly earnings report on Thursday, August 2nd.
On average, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $5.86 million for the current year, with estimates ranging from $5.16 million to $8.00 million. For the next financial year, analysts expect that the business will post sales of $54.03 million per share, with estimates ranging from $800,000.00 to $164.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative return on equity of 50.05% and a negative net margin of 199.55%. The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $4.04 million.
In related news, Director Douglas B. Given sold 25,000 shares of the stock in a transaction on Tuesday, April 24th. The stock was sold at an average price of $6.63, for a total value of $165,750.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kenneth Allen Myszkowski sold 20,000 shares of the stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $14.01, for a total value of $280,200.00. Following the completion of the transaction, the chief financial officer now directly owns 330,815 shares in the company, valued at approximately $4,634,718.15. The disclosure for this sale can be found here. In the last three months, insiders sold 59,000 shares of company stock worth $599,950. 4.60% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allianz Asset Management GmbH increased its stake in Arrowhead Pharmaceuticals by 2.2% in the fourth quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock valued at $1,701,000 after acquiring an additional 9,985 shares during the last quarter. Uniplan Investment Counsel Inc. increased its stake in Arrowhead Pharmaceuticals by 1.5% in the first quarter. Uniplan Investment Counsel Inc. now owns 724,228 shares of the biotechnology company’s stock valued at $5,221,000 after acquiring an additional 10,506 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new position in shares of Arrowhead Pharmaceuticals during the first quarter valued at about $100,000. Schwab Charles Investment Management Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 8.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 186,381 shares of the biotechnology company’s stock valued at $686,000 after buying an additional 15,132 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Arrowhead Pharmaceuticals during the first quarter valued at about $139,000. 46.31% of the stock is currently owned by institutional investors and hedge funds.
Shares of ARWR stock traded down $0.16 on Friday, reaching $13.31. The company’s stock had a trading volume of 159,470 shares, compared to its average volume of 2,432,364. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.16 and a current ratio of 10.16. Arrowhead Pharmaceuticals has a 12-month low of $1.48 and a 12-month high of $14.24. The company has a market capitalization of $1.16 billion, a PE ratio of -28.32 and a beta of 2.57.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.